Literature DB >> 24398404

The vesicular monoamine transporter 2: an underexplored pharmacological target.

Alison I Bernstein1, Kristen A Stout1, Gary W Miller2.   

Abstract

Active transport of neurotransmitters into synaptic vesicles is required for their subsequent exocytotic release. In the monoamine system, this process is carried out by the vesicular monoamine transporters (VMAT1 and VMAT2). These proteins are responsible for vesicular packaging of dopamine, norepinephrine, serotonin, and histamine. These proteins are essential for proper neuronal function; however, compared to their plasma membrane counterparts, there are few drugs available that target these vesicular proteins. This is partly due to the added complexity of crossing the plasma membrane, but also to the technical difficulty of assaying for vesicular uptake in high throughput. Until recently, reagents to enable high throughput screening for function of these vesicular neurotransmitter transporters have not been available. Fortunately, novel compounds and methods are now making such screening possible; thus, a renewed focus on these transporters as potential targets is timely and necessary.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  SLC18A2; Transport; VMAT2; Vesicle

Mesh:

Substances:

Year:  2014        PMID: 24398404      PMCID: PMC5028832          DOI: 10.1016/j.neuint.2013.12.003

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  134 in total

Review 1.  New insights into the mechanism of action of amphetamines.

Authors:  Annette E Fleckenstein; Trent J Volz; Evan L Riddle; James W Gibb; Glen R Hanson
Journal:  Annu Rev Pharmacol Toxicol       Date:  2007       Impact factor: 13.820

Review 2.  Vesicular neurotransmitter transporters as targets for endogenous and exogenous toxic substances.

Authors:  Farrukh A Chaudhry; Robert H Edwards; Frode Fonnum
Journal:  Annu Rev Pharmacol Toxicol       Date:  2008       Impact factor: 13.820

3.  Overexpression of the Drosophila vesicular monoamine transporter increases motor activity and courtship but decreases the behavioral response to cocaine.

Authors:  H-Y Chang; A Grygoruk; E S Brooks; L C Ackerson; N T Maidment; R J Bainton; D E Krantz
Journal:  Mol Psychiatry       Date:  2006-01       Impact factor: 15.992

4.  The effect of polychlorinated biphenyls on the high affinity uptake of the neurotransmitters, dopamine, serotonin, glutamate and GABA, into rat brain synaptosomes.

Authors:  E Mariussen; F Fonnum
Journal:  Toxicology       Date:  2001-02-21       Impact factor: 4.221

5.  Functional analysis of dopaminergic systems in a DYT1 knock-in mouse model of dystonia.

Authors:  Chang-Hyun Song; Xueliang Fan; Cicely J Exeter; Ellen J Hess; H A Jinnah
Journal:  Neurobiol Dis       Date:  2012-05-31       Impact factor: 5.996

6.  Polychlorinated biphenyl mixture aroclor 1254-induced oxidative stress plays a role in dopaminergic cell injury.

Authors:  D W Lee; L A Opanashuk
Journal:  Neurotoxicology       Date:  2004-12       Impact factor: 4.294

7.  Apomorphine increases vesicular monoamine transporter-2 function: implications for neurodegeneration.

Authors:  Jannine G Truong; Glen R Hanson; Annette E Fleckenstein
Journal:  Eur J Pharmacol       Date:  2004-05-25       Impact factor: 4.432

8.  Parkinson's disease and exposure to rural environmental factors: a population based case-control study.

Authors:  K M Semchuk; E J Love; R G Lee
Journal:  Can J Neurol Sci       Date:  1991-08       Impact factor: 2.104

9.  Vesicular monoamine transport inhibitors. Novel action at calcium channels to prevent catecholamine secretion.

Authors:  M Mahata; S K Mahata; R J Parmer; D T O'Connor
Journal:  Hypertension       Date:  1996-09       Impact factor: 10.190

10.  Polychlorinated biphenyl-induced reduction of dopamine transporter expression as a precursor to Parkinson's disease-associated dopamine toxicity.

Authors:  W Michael Caudle; Jason R Richardson; Kristin C Delea; Thomas S Guillot; Minzheng Wang; Kurt D Pennell; Gary W Miller
Journal:  Toxicol Sci       Date:  2006-05-15       Impact factor: 4.849

View more
  17 in total

Review 1.  Tardive Dyskinesia: Treatment Update.

Authors:  Divya Arya; Tarannum Khan; Adam J Margolius; Hubert H Fernandez
Journal:  Curr Neurol Neurosci Rep       Date:  2019-08-16       Impact factor: 5.081

2.  Sex and strain differences in dynamic and static properties of the mesolimbic dopamine system.

Authors:  Maria Teresa Rivera-Garcia; Aqilah M McCane; Tara G Chowdhury; Kathryn G Wallin-Miller; Bita Moghaddam
Journal:  Neuropsychopharmacology       Date:  2020-07-14       Impact factor: 7.853

Review 3.  Regulation of the Dopamine and Vesicular Monoamine Transporters: Pharmacological Targets and Implications for Disease.

Authors:  Christopher L German; Michelle G Baladi; Lisa M McFadden; Glen R Hanson; Annette E Fleckenstein
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

4.  Vesicular monoamine transporter 2 and the acute and long-term response to 3,4-(±)-methylenedioxymethamphetamine.

Authors:  Lucina E Lizarraga; Aram B Cholanians; Andy V Phan; Joseph M Herndon; Serrine S Lau; Terrence J Monks
Journal:  Toxicol Sci       Date:  2014-11-04       Impact factor: 4.849

5.  Synthesis of (±)-Tetrabenazine by Visible Light Photoredox Catalysis.

Authors:  Lindsey R Orgren; Emily E Maverick; Christopher C Marvin
Journal:  J Org Chem       Date:  2015-11-13       Impact factor: 4.354

6.  ApoE4 inhibition of VMAT2 in the locus coeruleus exacerbates Tau pathology in Alzheimer's disease.

Authors:  Seong Su Kang; Eun Hee Ahn; Xia Liu; Matthew Bryson; Gary W Miller; David Weinshenker; Keqiang Ye
Journal:  Acta Neuropathol       Date:  2021-04-25       Impact factor: 15.887

Review 7.  Aldehyde Dehydrogenase 1 making molecular inroads into the differential vulnerability of nigrostriatal dopaminergic neuron subtypes in Parkinson's disease.

Authors:  Huaibin Cai; Guoxiang Liu; Lixin Sun; Jinhui Ding
Journal:  Transl Neurodegener       Date:  2014-12-10       Impact factor: 8.014

8.  Efficient and biologically relevant consensus strategy for Parkinson's disease gene prioritization.

Authors:  Maykel Cruz-Monteagudo; Fernanda Borges; Cesar Paz-Y-Miño; M Natália D S Cordeiro; Irene Rebelo; Yunierkis Perez-Castillo; Aliuska Morales Helguera; Aminael Sánchez-Rodríguez; Eduardo Tejera
Journal:  BMC Med Genomics       Date:  2016-03-09       Impact factor: 3.063

9.  A Functional Vesicular Monoamine Transporter 1 (VMAT1) Gene Variant Is Associated with Affect and the Prevalence of Anxiety, Affective, and Alcohol Use Disorders in a Longitudinal Population-Representative Birth Cohort Study.

Authors:  Mariliis Vaht; Evelyn Kiive; Toomas Veidebaum; Jaanus Harro
Journal:  Int J Neuropsychopharmacol       Date:  2016-07-05       Impact factor: 5.176

10.  Comparison of In Vivo Gene Expression Profiling of RPE/Choroid following Intravitreal Injection of Dexamethasone and Triamcinolone Acetonide.

Authors:  Zeljka Smit-McBride; Elad Moisseiev; Sara P Modjtahedi; David G Telander; Leonard M Hjelmeland; Lawrence S Morse
Journal:  J Ophthalmol       Date:  2016-06-27       Impact factor: 1.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.